Compare GRFS & BTG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GRFS | BTG |
|---|---|---|
| Founded | 1940 | 2006 |
| Country | Spain | Canada |
| Employees | 25247 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Precious Metals |
| Sector | Health Care | Basic Materials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.8B | 7.2B |
| IPO Year | N/A | 2007 |
| Metric | GRFS | BTG |
|---|---|---|
| Price | $8.03 | $5.22 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 2 | 2 |
| Target Price | ★ $10.15 | $6.00 |
| AVG Volume (30 Days) | 646.0K | ★ 29.4M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 1.74% | 1.49% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $5.33 | $34.85 |
| Revenue Next Year | $6.50 | $23.18 |
| P/E Ratio | ★ $18.67 | $34.75 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $6.19 | $2.53 |
| 52 Week High | $11.14 | $6.29 |
| Indicator | GRFS | BTG |
|---|---|---|
| Relative Strength Index (RSI) | 30.37 | 46.12 |
| Support Level | $7.64 | $4.74 |
| Resistance Level | $9.11 | $5.89 |
| Average True Range (ATR) | 0.30 | 0.29 |
| MACD | -0.11 | -0.09 |
| Stochastic Oscillator | 4.38 | 18.06 |
Grifols SA one of is global specialty plasma therapeutics companies developing, manufacturing and distributing a broad range of biological medicines based on plasma derived proteins. Plasma derivatives are proteins found in human plasma, which once isolated and purified, have therapeutic value. These protein-based therapies extend and enhance the lives of individuals who suffer from chronic and acute, often life-threatening, conditions, including primary and secondary immunological deficiencies, Chronic Inflammatory Demyelinating Polyneuropathy, immune-mediated ITP. Products and services are used to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases and a range of other medical conditions. Majority of revenue is from USA.
B2Gold Corp is an international, low-cost, senior gold mining company. It has three operating open-pit gold mines in Mali, Namibia, and the Philippines and numerous exploration projects across four continents. Other assets include the Gramalote and Kiaka gold projects. The company focuses on acquiring and developing interests in mineral properties with a primary focus on gold deposits as gold production forms all its revenue. There is no dependence on a particular purchaser because the gold is sold into various markets. The company's reportable operating segments include its mining operations and development projects, namely Fekola; Masbate; Otjikoto; the Goose Project, and other mineral properties; and corporate and other.